Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0015672 (fatigue)
 51,768 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Interferons (IFNs)-alpha and -beta were administered to patients with metastatic sarcomas in two different Eastern Cooperative Oncology Group studies. In one study, patients received IFN-alpha 2b, 20 million units/m2 i.v. 5 days/week x 4, then 10 million units s.c.t.i.w. In the second study, patients received IFN-beta ser 180 million units t.i.w. Of 87 patients evaluable for response, there were three responses in 64 patients (5%) treated with IFN-alpha-2b and no responses in 23 patients treated with IFN-beta ser. Severe or life-threatening fatigue with decline in performance status complicated treatment of 37% of patients receiving IFN-alpha 2b and 17% of patients receiving IFN-beta ser. Further investigation of IFNs in sarcomas should depend on evidence from preclinical studies demonstrating synergistic effects of IFNs combined with a cytoreductive modality which has proven activity in these malignancies.
J Interferon Res 1992 Dec
PMID:Phase II trials of interferons-alpha and -beta in advanced sarcomas. 128 13

An interesting case of congenital intrapericardial aneurysm of the left-atrial appendage is reported. The patient presented with recurrent supraventricular arrhythmias and progressive exercise intolerance and fatigue. Computerised axial tomography aided in the diagnosis by excluding the presence of any thrombus in the sac. The aneurysm could be safely excised via a left thoracotomy without cardiopulmonary bypass. The relevant literature on this problem is briefly discussed.
Thorac Cardiovasc Surg 1992 Dec
PMID:Congenital intrapericardial aneurysm of the left-atrial appendage. 129 Jan 87

Eleven patients with hairy cell leukemia (HCL) were treated with YK-176 (2'-deoxycoformycin) at a dose of 5 mg/m2 by intravenous injection every week or every other week. Patients received a median of eight (range 4-19) injections of YK-176. Five patients had previously been untreated, four of whom had massive splenomegaly. Six patients had previously been treated, four with interferon-alpha (IFN-alpha) or IFN-alpha and chemotherapy and two with prednisolone. Two patients had had splenectomies. Five patients achieved complete remission (CR) and six, partial remission (PR) according to WHO criteria (remission rate 100%, 95% confidence interval (CI) 74-100%). All six neutropenic patients recovered > 1,500/microliters neutrophils, six of seven anemic patients recovered > 12.0 g/dl hemoglobin and five of nine thrombocytopenic patients recovered > 100,000/microliters platelets following the treatment. According to the response criteria for HLC, five patients achieved CR, two PR and four minor response. The overall remission (CR + PR) rate was 64% (95% CI 35-85%). The CR and PR have lasted from > 30 to > 718 days (median, > 281 days) so far with no relapses. Of four patients previously treated with IFN-alpha, two achieved CR and one, PR. All patients were alive with a median survival time of > 290 days from treatment (range > 50- > 763 days). The treatment was generally well tolerated. Mild to moderate nausea, vomiting, appetite loss and general fatigue were experienced in two patients, skin rash in one and a transient fever in three. YK-176 was a highly active agent in the treatment of HCL.
Jpn J Clin Oncol 1992 Dec
PMID:Treatment of hairy cell leukemia with deoxycoformycin (YK-176). The Deoxycoformycin (YK-176) Study Group. 129 57

Isradipine (Lomir) a new dihydropyridine calcium antagonist was evaluated for its efficacy, tolerability and safety among mild to moderate Tanzanian hypertensives. Twenty nine patients (7 males and 22 females), mean age 42.7 +/- 8.5 years entered active treatment phase, of the 16 week open label therapeutic trial. A mean decrease from base line in supine systolic blood pressure (SBP) of 17.6 mmHg (p < 0.001) and diastolic blood pressure (DBP) of 13.5 mmHg (p < 0.001) were achieved at the end of the study period. The corresponding changes from base line in standing SBP and DBP were 18 mmHg (p < 0.001) and 13.5 mmHg (p < 0.001) respectively. The efficacy was excellent or good in 84% and fair or none in 16% of the study patients. The tolerability of the drugs was excellent or good in 88.8% of patients, fair in 7.4% and bad in 3.8%. The mild side effects included headache, palpitations, tiredness and nocturia. But these improved with continued treatment. Isradipine (Lomir) at a dose of 1.25mg to 2.5mg twice daily is effective, safe and tolerable in mild to moderate hypertension.
East Afr Med J 1992 Dec
PMID:Efficacy, tolerability and safety of isradipine (Lomir) in the treatment of mild to moderate Tanzanian hypertensives. 129 33

Eleven subjects performed a graded exercise test after 1 week of protein supplementation (PRO) or glucose polymer placebo (CON), randomly assigned in a double blind fashion. The exercise consisted of 3-min graded exercise bouts separated by 10 min of active recovery at zero pedal resistance. Subjects then performed a 30-sec Wingate test (WIN) to assess performance during supramaximal exercise. Blood samples were obtained in the last 15 sec of each exercise and recovery period. PRO resulted in a decrease in blood lactate following 120% VO2max and WIN, an increase in blood alanine at all time points, and lower postexercise muscle lactate and glycogen. Resting muscle GPT activity was 47% higher during the PRO trial. Mean power output during the WIN did not differ between PRO and CON. The WIN fatigue index was not significantly different between PRO and CON. The increased alanine may reflect increased transamination of pyruvate, thereby reducing the accumulation of lactate, which in turn had a marginal effect on performance during supramaximal exercise.
Int J Sport Nutr 1992 Dec
PMID:The effect of protein supplementation on lactate accumulation during submaximal and maximal exercise. 129

A multicenter open trial involving 50 hypertension patients enabled evaluation of the efficacy and tolerability of Isoptine L.P. (sustained release verapamil) in mild to moderate essential hypertension. Following a 2-week placebo run-in period, patients were given Isoptine L.P. (240 mg/24 h) as a morning dose for 3 months, with a possible dose increase (360 mg/24 h) in case of diastolic blood pressure of 95 mmHg or more at the 30-day evaluation. Blood pressure was measured by mercury sphygmomanometer and, in 20 patients, by a Dinamap type Automatic device. After 3 months of treatment, blood pressure levels in supine and standing position, measured manually and automatically, showed a highly significant decrease, with a mean fall of 18.4 mmHg for systolic (13.7 percent) and 13.2 mmHg diastolic (-14.6 percent). 67 percent of patients were responders after 1 month of treatment and 79 percent at 3 months, including one-fifth at the dose of 360 mg/24 h. Seventeen patients, i.e. 34 percent, reported one or more adverse reactions. Among these, four patients had to stop treatment, twice because of headache and twice for constipation. Adverse events seen most frequently were constipation, headache, tiredness and vomiting. No cardiac adverse events were reported with the exception of one case of atrial premature contractions. The electrocardiogram revealed significant slowing of heart rate, as well as slight prolongation of PR and QT intervals and slight widening of the QRS complex. Tolerability on the basis of laboratory parameters was good.
Ann Cardiol Angeiol (Paris) 1992 Dec
PMID:[Efficacy and tolerability of isoptine LP in mild to moderate hypertension. A multicenter study with 50 patients]. 130 Sep 22

This study examined (a) the efficacy, and (b) predictors of outcome of a brief (one to four sessions) behavioral treatment program for chronic insomnia. A total of 103 insomnia patients were treated, and outcome was assessed by a follow-up questionnaire. Outcome variables, including both nocturnal sleep parameters and measures of daytime functioning, showed significant improvement subsequent to treatment. Pretreatment sleep hygiene practices were significantly correlated with daytime fatigue and sleep latency outcome factors. Pre- and post-treatment complaints of daytime fatigue were associated with somatic complaints in general, but not with nocturnal sleep variables. Explanatory hypotheses are discussed.
J Behav Ther Exp Psychiatry 1992 Dec
PMID:Assessment and prediction of outcome for a brief behavioral insomnia treatment program. 130 54

1. The skeleto-fusimotor or beta innervation was compared in cat peroneus brevis and peroneus tertius muscles, which differ in their composition of fatigue-resistant motor units; the slow (S) units predominate in brevis and the fast units (FR) in tertius. 2. In four brevis muscles, of thirty-four beta-axons (from a total of 114 axons supplying extrafusal muscle fibres) twenty-nine were dynamic (beta D) and only five static (beta S). In contrast, in three tertius muscles, of twenty-five beta-axons (from a total of 82 axons) twelve were static and thirteen dynamic. 3. In a population of thirty-five brevis and thirty tertius spindles, the proportion of beta D-innervated spindles was greater in the brevis (68.5%) than in the tertius (50%) whereas that of beta S-innervated spindles was greater in the tertius (40%) than in the brevis (17.1%). In a population of thirty-two brevis and twenty-seven tertius spindles in which the presence of bag1 fibres was deduced from the existence of a dynamic innervation, the proportion of spindles innervated by beta D-axons was 80% in the brevis and 62% in the tertius. 4. In both muscles, the number of beta D effects was greater than that of beta S effects. beta S-axons were rarely found to supply more than one spindle whereas beta D-axons supplying more than one spindle (up to four) were common. Spindles were often coinnervated by beta D- and beta S-axons.(ABSTRACT TRUNCATED AT 250 WORDS)
J Physiol 1992 Dec
PMID:Comparison of skeleto-fusimotor innervation in cat peroneus brevis and peroneus tertius muscles. 130 77

The dorsal cortex of the equine third metacarpal mid-diaphyseal bone was characterised during growth by the histological and microradiographic examination of specimens from 30 horses ranging in age from 2 months to 8 y. Bone from horses aged less than 6 months was characterised by rapid periosteal apposition of circumferential trabeculae of woven bone that were next connected by radial trabeculae to the parent cortex. Deposition of lamellar bone on the inner trabecular surfaces resulted in rows of primary osteons. Replacement of primary bone occurred only after 4 months of age and preferentially in the woven interstitial bone separating rows of primary osteons formed in the postnatal periosteal cortex. Resorption cavities and incompletely filled secondary osteons characterised bone of 1 and 2-y-old horses. Bone from horses older than 3 y contained several generations of secondary osteons, fewer resorption spaces and incompletely filled osteons, and had a greater portion of circumferentially oriented collagen fibres than bone from younger horses. Bone from horses older than 5 y had large resorption cavities characterised by irregular boundaries. We propose that the process of periosteal bone tissue apposition observed in growing foals be called 'saltatory primary osteonal bone formation' and that this process results in faster cortical expansion and larger total surface area for bone deposition than circumferential lamellar, simple primary osteonal, and plexiform mechanisms of periosteal bone formation. We speculate that bone from 1 and 2-y-old horses would be more susceptible to fatigue microdamage resulting from compressive loads because of high porosity, few completed secondary osteons and low proportion of circumferentially oriented collagen fibres.
J Anat 1992 Dec
PMID:Histological features of the dorsal cortex of the third metacarpal bone mid-diaphysis during postnatal growth in thoroughbred horses. 130 84

A new tensile fatigue test using a stainless steel screw was introduced. A transparent PMMA rod was selected as the test material. A hole was drilled and tapped into the rod; a screw was put into the rod with dental cement or without cementation. Three types of cyclic loads were applied to the test piece; the number of times the load was applied when the initial crack was observed and when the final fracture occurred were recorded. Surface observation showed that actual fatigue fractures occurred in the test piece. The preferred applied load waveform was the cyclic haver-triangles load because of the small coefficient of variance. Fatigue strengths of test pieces with and without cementation were different. Cementation improved the fatigue properties, and the type of cement had an effect on the fatigue properties. Although the number of final fractures minus the number of initial cracks was the constant regardless of the type of cement used.
Dent Mater J 1992 Dec
PMID:A new procedure of the tensile fatigue test for dental materials. 130 70


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>